Clinical trials: TACE
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib
The purpose of this study is to evaluate the safety and efficacy of the combination therapy with Transcatheter Arterial Chemoembolization (TACE) and sorafenib compared to TACE alone in patients with unresectable hepatocellular…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Carcinoma, Hepatocellular, Liver Neoplasm
- Trial name
- TACTICS (NCT01217034)
- Testing
- TACE with sorafenib, TACE alone
- Where
- Japan
- Volunteers
- 228 people
- Sponsor
- Kindai University
Liver Cancer
HAIC-TACE Plus Apatinib and Camrelizumab for Liver Cancer
To provide evidence-based medical evidence for the optimized combination strategy of local and systemic therapies.
- Trial name
- NCT07587034
- Testing
- HTAC, HAC, TAC
- Volunteers
- 315 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with PD-1/PD-L1 Inhibitors and molecular target therapies in patients with Intermediate-stage…
- Trial name
- CHANCE2202 (NCT05332496)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 941 people
- Sponsor
- Zhongda Hospital
Intrahepatic Cholangiocarcinoma
TACE Combined With "Target Immune" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma
This study is a prospective, multicenter, open, real-world clinical study. All eligible patients were assigned to experimental group (TACE combined with multi-target drugs and PD-1 inhibitors), and control group (conventional…
- Trial name
- NCT05247996
- Testing
- Transcatheter arterial chemoembolization, Multi-target Drug Therapy, Immunocheckpoint Inhibitor Therapy
- Volunteers
- 98 people
- Sponsor
- The Central Hospital of Lishui City
Unresectable Hepatocellular Carcinoma
A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer
This study is a multicenter, registered research aimed at evaluating the efficacy of different treatment regimens in the treatment of unresectable CNLC liver cancer stage III hepatocellular carcinoma
- Trial name
- NCT05660213
- Testing
- Targeted drugs combined with anti-PD-1/PD-L1 antibodies, TACE (transarterial chemoembolization) combined with targeted/immunotherapy, Lenvatinib monotherapy
- Volunteers
- 750 people
- Sponsor
- Fudan University
Hepatocellular Carcinoma
TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC
The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage…
- Trial name
- CHANCE2201 (NCT05332821)
- Testing
- PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE
- Where
- 2 sites in China
- Volunteers
- 1,244 people
- Sponsor
- Zhongda Hospital
Carcinoma, Hepatocellular
Adjuvant TACE to Reduce the HCC Recurrence After Resection
Hepatocellular carcinoma (HCC) is the sixth most common malignancies worldwide and the second leading cause of cancer-related death.
- Trial name
- NCT02788526
- Testing
- Adjuvant TACE, Follow-up
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable
Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma
The study investigates the adjuvant SBRT following TACE in early and intermediate stages HCC not amenable for surgical resection.
- Trial name
- ASTrH (NCT04996914)
- Testing
- TACE, SBRT
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- RWTH Aachen University
Hepatocellular Carcinoma
Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer
Patients with liver cancer will receive interventional therapy plus radiotherapy. Maintenance Sorafenib will be taken after the completion of radiotherapy.
- Trial name
- NCT00999843
- Testing
- Sorafenib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Fudan University
Hepatocellular Cancer
Interest of elastoFRM With Force Measure by MRI on Patients With Hepatocellular Cancer
FORCE project aims to measure actives forces of malignant tumor by magnetic resonance force (FRM). Two main forces are considered as key indicators of therapeutic response and metastatic potential: interstitial force and traction…
- Trial name
- FORCE (NCT02929082)
- Testing
- IRM with a 5-minute- additional sequence to measure FRM
- Where
- France
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma
Cadonilimab is a first-in-class bispecific, humanized IgG1 antibody targeting PD-1 and CTLA-4, which has the potential to boost immune surveillance in tumors.
- Trial name
- NCT05925413
- Testing
- Cadonilimab+TACE
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
To Evaluate Safety and Efficacy of FB-1603 in Hepatocellular Carcinoma Patient Receiving Transarterial Chemoembolization
The goal of this clinical trial is to assess the efficacy of FB-1603 on improving liver function impairment in hepatocellular carcinoma patients receiving transarterial chemoembolization.
- Trial name
- NCT06478719
- Testing
- FB-1603
- Where
- 2 sites in Taiwan
- Volunteers
- 120 people
- Sponsor
- Febico Biomedical Corp.
Hepatocellular Carcinoma
Sorafenib Chemoembolization Evaluation Controlled Trial
This prospective, multicenter, randomized, controlled study aims to evaluate the efficacy and safety of sorafenib combined with transarterial chemoembolization (TACE) in advanced hepatocellular carcinoma (HCC) patients compared…
- Trial name
- SELECT (NCT01906216)
- Testing
- Sorafenib, TACE
- Where
- China
- Volunteers
- 199 people
- Sponsor
- Air Force Military Medical University, China
Huge Hepatocellular Carcinoma (HCC) (≥10cm)
Safety and Efficacy of GSMs-TACE Combined With Surgical Resection in Treatment of Huge Hepatocellular Carcinoma (HCC) (≥10cm)
A Single center, Open, Randomized Controlled Trial Evaluating the Safety and Efficacy of GSMs-TACE combined with Surgical Resection in Treatment of Huge Hepatocellular Carcinoma (HCC) (≥10cm).
- Trial name
- NCT04619329
- Testing
- GSMs-TACE, Surgical Resection
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Colorectal Cancer
An Exploratory Study of Sequential Transarterial Chemoembolization With Lipiodol and Neoadjuvant Chemotherapy in the Treatment of Initial Unresectable Colorectal Cancer (CRC)
This is a prospective, open-labelled study to evaluate the efficacy and safety of sequetial transarterial chemoembolization with lipiodol and neoadjuvant chemotherapy in the treatment of initial unresectable colorectal cancer.
- Trial name
- NCT05340231
- Testing
- TACE protocol, Neoadjuvant Chemotherapy
- Volunteers
- 100 people
- Sponsor
- Gang Wu
Transcatheter Arterial Chemoembolization, Unresectable Hepatocellular Carcinoma
A Generative Model-based System for Predicting Survival and Guiding Treatment Decisions in Patients With Unresectable Hepatocellularcarcinoma Undergoing Transcatheter Arterial Chemoembolization in Combination With Immunotherapy and Targeted Therapy
The entry point of this study is the proposition of "generative longitudinal prediction," which utilizes only pre-treatment imaging to create high-fidelity predictions of post-treatment imaging.
- Trial name
- NCT07065786
- Testing
- Generative model
- Where
- China
- Volunteers
- 550 people
- Sponsor
- Zhongda Hospital
Primary Hepatocellular Carcinoma, Portal Vein Thrombosis
H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis
This study is the first to compare the efficacy and safety of recombinant human adenovirus type 5 injection via hepatic artery infusion combined with TACE-based combination therapy for the treatment of patients with stage IIIa…
- Trial name
- NCT05872841
- Testing
- Recombinant human adenovirus type 5 + TACE
- Volunteers
- 38 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepatocellular Carcinoma, Programmed Cell Death 1
Real-world Study of Efficacy and Safety of ICIs and TKIs Therapy for HCC
China is a high-risk area of Hepatocellular Carcinoma (HCC). Although Chinese population accounts for 18.4% of the global population, the number of new HCC patients accounting for about half of the global, which seriously…
- Conditions
- Hepatocellular Carcinoma, Programmed Cell Death 1, Effects of Immunotherapy
- Trial name
- NCT05420922
- Testing
- Lenvatinib Oral Product, PD-1 inhibitor, Local treatment
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Tongji Hospital
Hepatocellular Carcinoma
The Combination Therapy of TACE and Ablation With Durvalumab in Hepatocellular Carcinoma at Intermediate Stage (TAD)
This is a pilot study with a single arm in a single center assessing safety and efficacy of combination therapy of TACE and ablation and durvalumab.
- Trial name
- NCT04517227
- Testing
- Durvalumab, Transcatheter Hepatic Arterial Chemoembolization (TACE), Ablation
- Volunteers
- 30 people
- Sponsor
- Fudan University
Unresectable Hepatocellular Carcinoma, Portal Vein Thrombosis
SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT
To evaluate and compare the efficacy and safety of SBRT sequential TACE combined with sorafenib versus sorafenib alone in the treatment of unreactable HCC with PVTT.
- Trial name
- NCT04387695
- Testing
- SBRT+TACE+Sorafenib, Sorafenib
- Where
- China
- Volunteers
- 54 people
- Sponsor
- First Affiliated Hospital of Zhejiang University